DDInter604 DDInter1907
Drospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with [Ethinyl estradiol]. Most recently, it was approved by both Health Canada and the FDA in combination with [Estetrol] as an oral contraceptive therapy.[L33199,L33174] Aside from its contraceptive effects, drospirenone is used with estrogens to control acne and premenstrual dysphoric disorder (PMDD). Drospirenone has been the subject of widespread safety concern due to the possibility of an increased risk of venous thromboembolism associated with its use.[A182543,A182552] In 2012, however, a safety statement by the FDA concluded that the increase in the risk of thromboembolism resulting from the use of drospirenone remains unclear, as studies regarding this risk are conflicting. Some studies have demonstrated a significantly increased risk and some demonstrating no risk of thrombo
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling pathways. The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and active psoriatic arthritis, alone or in combination with [methotrexate]. In September 2016, ustekinumab was additionally approved for the management of moderate to severe Crohn's disease in selected adult patients. In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults. Ustekinumab is currently the first and only approved biologic therapy for ulcerative colitis that targets the interleukin (IL)-12 and IL-23 cytokines. The dosing regimen for ustekinumab is based on the patient's weight and there are intravenous and subcutaneous formulations of the drug based on the dosing schedule and condition being treated. Ustekinumab is commonly marketed under the trade name STELARA. Ustekinumab biosimilars are available in some markets, including Wezlana (ustekinumab-auub) in the US and Jamteki (AVT04) in Canada.
Drospirenone {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Drospirenone {u} (Compound) resembles {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Drospirenone {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ixekizumab
Ixekizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Drospirenone {u} (Compound) resembles {v} (Compound) Flurandrenolide
Flurandrenolide {u} (Compound) resembles {v} (Compound) Budesonide
Budesonide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Drospirenone {u} (Compound) resembles {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ustekinumab
Drospirenone {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Escherichia coli
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Drospirenone {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} (Compound) resembles {v} (Compound) Norgestimate
Norgestimate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Drospirenone {u} (Compound) resembles {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Zinc gluconate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ustekinumab
Drospirenone {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Drospirenone {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Drospirenone (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Drospirenone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Drospirenone (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Drospirenone (Compound) resembles Flurandrenolide (Compound) and Flurandrenolide (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Drospirenone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Drospirenone (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Drospirenone (Compound) resembles Progesterone (Compound) and Progesterone (Compound) resembles Norgestimate (Compound) and Norgestimate may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Drospirenone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Drospirenone (Compound) resembles Progesterone (Compound) and Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Drospirenone (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab